Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-07-07
1996-04-23
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 15, 514 16, 514 17, 514 18, 530327, 530328, 530329, 530330, 530345, A61K 3800, C07K 100
Patent
active
055103324
ABSTRACT:
The present invention is directed to an isolated and purified peptide comprising the LDV domain of the CSI peptide sequence or single amino acid substitutent analog thereof. A preferred peptide has the amino acid residue sequences shown in SEQ ID NOs:8-14, 17-23, 25, 28, and 51. The present invention is further directed to a process of inhibiting the binding of .alpha..sub.4 .beta..sub.1 integrin to a protein such as VCAM-1 or fibronectin comprising exposing a cell that expresses .alpha..sub.4 .beta..sub.1 integrin to the protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition comprising a peptide of SEQ ID NO:8-102.
REFERENCES:
patent: 5405831 (1995-04-01), MacIntyre
The Journal of Cell Biology, Activation-dependent Recognition by Hematopoietic Cells of the LDV Sequence in the V Region of Fibronectin; E. A. Wayner and N. L. Kovach, vol. 116, No. 2, 489-497 (Jan. 1992).
Cell, Phosphatidylinositol 3-Kinase: Structure and Expression of the 110 kd Catalytic Subunit, Hiles et al., vol. 70, 419-429 (Aug. 7, 1992).
Journal of Cell Science, VCAM-1 is a CS1 peptide-inhibitable adhesion molecule expressed by lymph node high endothelium, May et al., vol. 106, 109-119 (1993).
American Journal of Pathology, Rapid Communication-Alternative Splicing of Human VCAM-1 in Activated Vascular Endothelium, Cybulski et al., vol. 138, No. 4, 815-820, (Apr. 1991).
The Journal of Biological Chemistry, Competitive Binding of Vascular Cell Adhesion Molecule-1 and the HepII/IIICS Domain of Fibronectin to the Integrin .alpha.4.beta.1, Makarem et al., vol. 269, No. 6, 4005-4011 (Feb. 1994).
Cell, VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site, Elices et al. vol. 60, 577-584, (1990).
Cell, Direct Expression Cloning of Vascular Cell Adhesion Molecule 1, a Cytokine-Induced Endothelial Protein That Binds to Lymphocytes, Osborn et al., vol. 9, 1203-1211, (1989).
Science, An Inducible Endothelial Cell Surface Glycoprotein Mediates Melanoma Adhesion, G. Edgar Rice and Michael P. Bevilacqua, vol. 246, 1303-1306 (Dec. 1989).
The Journal of Biological Chemistry, Cloning of an Alternate Form of Vascular Cell Adhesion Molecule-1 (VCAM1), Hession et al., vol. 266, Issue No. 11, 6682-6685 (1991).
J. Exp. Med., Lymphocyte Adhesion through Very Late Antigen 4: Evidence for a Novel Binding Site in thew Alternatively Spliced Domain of Vascular Cell Adhesion Molecule 1 and an Additional .alpha.4 Integrin Counter-Receptor on Stimulated Endothelium, Robert H. Vonderheide and Timothy A. Springer, vol. 175, 1433-1442 (Jun. 1992).
J. Exp. Med., Activated Endothelium Binds Lymphocytes Through a Novel Binding Site in the Alternatively Spliced Domain of Vascular Cell Adhesion Molecule-1, Laurelee Osborn and Christopher D. Benjamin, vol. 176, 99-107 (Jul. 1992).
The Journal of Biological Chemistry, VLA-4 Integrin Mediates Lymphocyte Migration of the Inducible Endothelial Cell Ligand VMCA-1 and the Extracellular Matrix Ligand Fibronectin, Po-Ying Chan and Alejandro Aruffo, vol. 268, No. 33, 24655-24664 (Nov. 24, 1993).
The EMBO Journal, Identification of a novel recognition sequence for the integrin .alpha.4.beta.1 in the COOH-terminal heparin-binding domain of fibronectin, A. Paul Mould and Martin J. Humphries, vol. 10, No. 13, 4089-4095 (1991).
J. Clin Invest. VLA-4 Integrin Can Mediate CD11/CD18-independent Transendothelial Migration of Human Monocytes, H. Eduardo Chuluyan and Andrew C. Issekutz, vol. 92, 2768-2777 (Dec. 1993).
Nature, Prevention of experimental autoimmun e encephalomyelitis by antibodies against .alpha.4.beta.1 integrin, Yednock et al., vol. 356, 63-66 (5 Mar. 1992).
Eur J. Immunol, Monoclonal antibodies to the integrin .alpha.-4 subunit inhibit the murine contact hypersensitivity response, Chisholm et al., vol. 23, 682-688 (1993).
The Journal of Biological Chemistry, Multiple Activation States of VLA-4, Akihide Masumoto and Martin E. Hemler, vol. 268, No. 1, 228-234 (Jan. 5, 1993).
1994 Current Drugs Ltd., Abstract of Publication No. WO9402445, Non-peptidic surrogates of the LDV sequence and their use in the treatment of inflammation, autoimmune diseases and tumour progression, Lider et al.
The Journal of Biological Chemistry, The CS5 Peptide Is a Second Site in the IIICS Region of Fibronectin Recognized by the Integrin .alpha..sub.4 .beta..sub.1 , Mould et al., vol. 266, No. 6, 3579-3585 (Feb. 25, 1991).
Beck Pamela J.
Kogan Timothy P.
Ren Kaijun
Vanderslice Peter
Chan Christina Y.
Prickril Benet
Texas Biotechnology Corporation
LandOfFree
Process to inhibit binding of the integrin .alpha..sub.4 62 .sub does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process to inhibit binding of the integrin .alpha..sub.4 62 .sub, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process to inhibit binding of the integrin .alpha..sub.4 62 .sub will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2308520